MARKET

ALIM

ALIM

Alimera Sciences
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.590
-0.270
-5.56%
Closed 16:00 09/20 EDT
OPEN
4.780
PREV CLOSE
4.860
HIGH
4.875
LOW
4.574
VOLUME
19.54K
TURNOVER
--
52 WEEK HIGH
12.25
52 WEEK LOW
3.821
MARKET CAP
31.78M
P/E (TTM)
50.77
1D
5D
1M
3M
1Y
5Y
Alimera Sciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference
ATLANTA, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concern...
GlobeNewswire · 09/02 20:30
Alimera Sciences Shares Spike To Session High Following Sam.gov $3.4M Contract Award Via Dept. Of Veterans Affairs
https://sam.gov/opp/afee7b92a92a40b5a35d984e0359693d/view
Benzinga · 08/27 17:01
Alimera Sciences Announces National Pricing and Reimbursement Granted for ILUVIEN(R) for DME in Belgium
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, announces that Alimera Sciences Europe Limited, its Ireland-based European subsi...
GlobeNewswire · 08/24 12:00
Trillium Therapeutics, Vivos Therapeutics leads healthcare gainers; Flora Growth, Surgalign among major losers
Gainers: Trillium Therapeutics TRIL +187%, Vivos Therapeutics VVOS +57%, Xeris Pharmaceuticals XERS +19%, ALX Oncology (NASDAQ:ALXO) +24%, Candel Therapeutics (NASDAQ:CADL) +20%. Losers: Flora Growth (NASDAQ:FLGC) -10%, Surgalign (NASDAQ:SRGA) -9%, Alimera...
Seekingalpha · 08/23 15:05
JW Asset Management, LLC Buys Pharming Group, AdvisorShares Pure US Cannabis ETF, Medicus ...
GuruFocus News · 08/20 19:38
New Strong Sell Stocks for August 19th
Zacks.com · 08/19 13:04
--Alliance Global Partners Adjusts Alimera Sciences PT to $14.50 From $16.50, Maintains Buy Rating
MT Newswires · 08/17 11:04
Ocular Drug Delivery Technology Market Size, Share, Trends, Analysis and Forecast 2027
The Global is estimated to value over USD 19 billion by 2027 end at a CAGR of over 6.8% during the forecast period 2020 to 2027.
Market Insight Reports · 08/17 07:10
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALIM. Analyze the recent business situations of Alimera Sciences through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALIM stock price target is 14.83 with a high estimate of 18.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 56
Institutional Holdings: 31.66M
% Owned: 457.20%
Shares Outstanding: 6.92M
TypeInstitutionsShares
Increased
11
119.08K
New
3
32.02K
Decreased
4
36.55K
Sold Out
3
37.99K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.35%
Pharmaceuticals & Medical Research
-1.08%
Key Executives
Non-Executive Chairman
C. Daniel Myers
President/Chief Executive Officer/Director
Richard Eiswirth
Chief Financial Officer
J. Phillip Jones
Chief Operating Officer/Senior Vice President
Philip Ashman
Senior Vice President/Chief Marketing Officer
David Holland
Lead Director/Independent Director
James Largent
Independent Director
Brian Halak
Independent Director
Garheng Kong
Independent Director
Peter Pizzo
Independent Director
John Snisarenko
No Data
About ALIM
Alimera Sciences, Inc. is a pharmaceutical company. The Company is engaged in commercialization and development of prescription ophthalmic pharmaceuticals. It focuses on diseases affecting the back of the eye or retina. The Company’s commercial product, ILUVIEN, is an intravitreal implant, which treats patients by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. It is engaged in developing for the treatment of diabetic macular edema (DME). DME is a disease of retina that affects individuals with diabetes and can lead to severe vision loss and blindness. ILUVIEN can also be used to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). The Company commercially market ILUVIEN directly in the United States, Germany, United Kingdom, Portugal, and Ireland.

Webull offers kinds of Alimera Sciences Inc stock information, including NASDAQ:ALIM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALIM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALIM stock methods without spending real money on the virtual paper trading platform.